In the search for more potent, safe and effective autophagy inhibitor compounds, researchers from the Wayne State University School of Medicine have developed novel piperazine- and piperidine-substituted quinoline derivatives GL-287 and GL-382, based on the quinoline scaffold of hydroxychloroquine.
Researchers from Excision Biotherapeutics Inc. and affiliated organizations have reported the development of a novel CRISPR/Cas9-mediated genome editing therapy – EBT-104 – for the treatment of latent herpes simplex virus 1 (HSV-1) keratitis.
Find Therapeutics Inc. has obtained FDA clearance of its IND application for FTX-101, a first-in-class remyelinating agent that aims to restore vision in people with chronic optic neuropathy.
Innovec Pharmaceutical Technology Co. Ltd. (Innovec Biotherapeutics) has received FDA clearance for its IND application for IVB-103, an AAV-based gene therapy for neovascular age-related macular degeneration (AMD).
Aldeyra Therapeutics Inc. has bounced back from a complete response letter in November to produce positive phase III data for reproxalap in treating dry eye disease. The company is one of many developing treatments using diverse mechanisms of action.
Kodiak Sciences Inc. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of age-related macular degeneration, choroidal neovascularization, diabetic macular edema, dry eye, glaucoma, bacterial keratitis, retinitis and uveitis, among others.
Nurexone Biologic Inc. has announced preliminary results from a small-scale controlled study at Sheba Medical Center exploring the use of nanodrug Exopten for optic nerve recovery in a rat model. An optic nerve crush (ONC) model was used to simulate conditions such as glaucoma, where the optic nerve is damaged, resulting in impaired vision.
As the hunt goes on for a better treatment in wet age-related macular degeneration (AMD), landmark analyses of two batches of phase II gene therapy data billed as positive were disclosed during the American Society of Retina Specialists annual meeting in Stockholm, where 4D Molecular Therapeutics Inc. and Adverum Biotechnologies Inc. offered findings.
Beyond its success in migraine and attention deficit hyperactivity disorder, Nu Eyne Co. Ltd. is advancing a portfolio of noninvasive, wearable trigeminal nerve stimulation devices across key three areas of neuromodulation, tissue regeneration and proliferation inhibition.
Nexthera Co. Ltd. has submitted an IND application to the FDA seeking to conduct a phase I/IIa trial with NT-101, a noninvasive eye drop treatment for wet age-related macular degeneration (AMD).
RSS
